NCT07362693

A Cohort Study of the Efficacy and Safety of Biologics in Patients With ABPA

A Prospective, Multicenter, Observational Cohort Study on the Efficacy and Safety of Biological Agents in Patients With Allergic Bronchopulmonary Aspergillosis

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 50 (estimated)
• Sponsor: Qianfoshan Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the efficacy and safety of biological agents in patients with allergic bronchopulmonary aspergillosis.

Conditions

• ABPA
• Biologics
• Allergic Bronchopulmonary Aspergillosis (ABPA)
• Cohort Study
• Allergic Bronchopulmonary Aspergillosis
• Efficacy and Safety

Interventions

Type	Name	Description
DRUG	Biologic Agent	On the basis of the original standard drug treatment, biological agents were combined. All patients received at least 4 months of the same biologic agent, as recommended by the GINA2025 guidelines and assessed for response. It can be administered simultaneously with standard medical therapy or as maintenance therapy for 4 months on standard medical therapy. The previous treatment for bronchial asthma was maintained, including inhaled corticosteroids + long-acting β-receptor agonists, leukotriene receptor antagonists, etc.

Timeline

• Start date: 2025-01-31
• Primary completion: 2028-12-31
• Completion: 2028-12-31
• First posted: 2026-01-23
• Last updated: 2026-04-17

Locations

1 site across 1 country: China

Regulatory

• FDA-regulated drug study